Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

Journal article

BACKGROUND: Chemoradiation became the standard of care for anal cancer after the ACT I trial. However, only two-thirds of patients achieved local control, with 5-year survival of 50%; therefore, better treatments are needed. We investigated whether replacing mitomycin with cisplatin in chemoradiation improves response, and whether maintenance chemotherapy after chemoradiation improves survival. METHODS: In this 2 × 2 factorial trial, we enrolled patients with histologically confirmed squamous...

Expand abstract

Authors: James, R; Glynne-Jones, R; Meadows, H; Cunningham, D; Myint, A

• Publication status: Published
• Journal: Lancet. Oncology
• Volume: 14
• Issue: 6
• Pages: 516-524
• Publication date: 2013-05-01
• DOI: 10.1016/s1470-2045(13)70086-x
• EISSN: 1474-5488
• ISSN: 1470-2045
• Language: English
• Keywords: Great Britain; Disease-Free Survival; Carcinoma, Squamous Cell; Female; Middle Aged; Cisplatin; Kaplan-Meier Estimate; Male; Intention to Treat Analysis; Proportional Hazards Models; Treatment Outcome; Time Factors; Fluorouracil; Humans; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Neoplasm Recurrence, Local; Mitomycin; Anus Neoplasms; Drug Administration Schedule; Dose Fractionation; Aged